Age-Related Changes in Pharmacodynamics — MCQs
What is the most consistent cardiovascular effect of hypothermia in elderly patients?
Newborns as compared to adults eliminate lidocaine:
Which of the following drug causes postural hypotension commonly?
Which of the following statements about the differences between neonates and adults is true?
All of the following drugs cross the blood-brain barrier, EXCEPT:
Which of the following is not a component of the Goldman Revised Cardiac Risk Index?
A mother reports that her daughter ingested a substance in an unknown dose. The girl presents with hypertension, tachycardia, mydriasis, and hyperthermia. What is the most likely substance?
What do A and B represent in the curve shown below?
For the treatment of kala-azar, the daily dose of miltefosine in a 3-year-old child who weighs 15 kg is
Which of the following is a characteristic feature of Werner's syndrome?
Age-Related Changes in Pharmacodynamics Indian Medical PG Practice Questions and MCQs
Question 1: What is the most consistent cardiovascular effect of hypothermia in elderly patients?
- A. May cause myocardial infarction
- B. Decreased heart rate (Correct Answer)
- C. Decreased cardiac output
- D. All of the options
Explanation: ***Decreased heart rate*** - In elderly patients, **hypothermia consistently leads to a decrease in heart rate (bradycardia)**, a physiological response to conserve energy and reduce metabolic demand - This **bradycardia** is a hallmark sign of hypothermia across various age groups, but it is particularly pronounced and dangerous in the elderly due to their reduced physiological reserve - **Heart rate decreases by approximately 3-5 beats per minute for every 1°C drop in core temperature** below 35°C, making it the most predictable and consistent cardiovascular finding *May cause myocardial infarction* - While severe hypothermia can precipitate **myocardial ischemia or infarction** due to increased myocardial oxygen demand from shivering, catecholamine release, and coronary vasoconstriction, it is not the *most consistent* cardiovascular effect across all degrees of hypothermia - **Myocardial infarction** is a serious complication, but occurs less predictably than bradycardia and depends on pre-existing coronary artery disease *Decreased cardiac output* - **Cardiac output** does generally decrease in hypothermia due to the combined effects of **bradycardia and reduced myocardial contractility** - However, the initial and most consistent direct effect is the **slowing of the heart rate**, which then contributes to the overall decrease in cardiac output - Cardiac output falls by approximately **25-40% at core temperatures below 32°C** *All of the options* - While hypothermia can contribute to myocardial infarction and does decrease cardiac output, the **most consistent and universal cardiovascular effect is bradycardia** - Not all hypothermic patients will develop MI, and the decrease in cardiac output is a *consequence* of bradycardia and reduced contractility rather than a primary direct effect
Question 2: Newborns as compared to adults eliminate lidocaine:
- A. Variable
- B. More rapidly
- C. Equally fast
- D. More slowly (Correct Answer)
Explanation: ***More slowly*** - Newborns have **immature hepatic enzyme systems**, particularly for **CYP1A2** and **CYP3A4**, which are crucial for lidocaine metabolism. - Reduced **plasma protein binding** and a larger **volume of distribution** in newborns can also impact lidocaine clearance, leading to slower elimination. *Variable* - While there can be individual variability in drug metabolism, the general trend for lidocaine elimination in newborns is consistently slower due to physiological immaturity, not merely variable. - This option does not capture the overall physiological characteristic of drug elimination in neonates. *More rapidly* - This is incorrect because newborns have underdeveloped liver function and enzyme systems, which would hinder, not accelerate, the metabolism and elimination of drugs like lidocaine. - A more rapid elimination would suggest a highly efficient metabolic pathway, which is not the case in neonates. *Equally fast* - This is incorrect as the **pharmacokinetic profile** of drugs, including lidocaine, differs significantly between newborns and adults due to developmental differences in organ function (e.g., liver, kidneys). - The liver's metabolic capacity in newborns is not fully mature enough to eliminate lidocaine at the same rate as in adults.
Question 3: Which of the following drug causes postural hypotension commonly?
- A. Alpha blocker (Correct Answer)
- B. Angiotensin receptor blockers
- C. Beta blocker
- D. ACE inhibitor
Explanation: ***Alpha blocker*** - **Alpha-1 adrenergic blockers** cause common postural hypotension by blocking **alpha-1 receptors** on vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance. - This vasodilation, especially in the upright position, can cause blood to pool in the lower extremities, decreasing venous return to the heart and thus lowering blood pressure. *Angiotensin receptor blockers* - These drugs block the effects of **angiotensin II**, leading to vasodilation and decreased aldosterone secretion, typically causing a more gradual and less pronounced drop in blood pressure. - While they can cause hypotension, **postural hypotension** is less common and usually less severe compared to alpha blockers due to their different mechanism of action and less abrupt vasodilation. *Beta blocker* - **Beta-blockers** primarily reduce heart rate and myocardial contractility, thereby decreasing cardiac output, which can contribute to generalized hypotension. - They do not directly cause significant **vasodilation** in the same manner as alpha-blockers, making postural hypotension less common unless there are other contributing factors. *ACE inhibitor* - **ACE inhibitors** prevent the conversion of angiotensin I to **angiotensin II**, leading to vasodilation and reduced aldosterone. - They can cause hypotension, especially with the first dose or in volume-depleted patients, but **postural hypotension** is typically less frequent and severe than with alpha-blockers.
Question 4: Which of the following statements about the differences between neonates and adults is true?
- A. They can tolerate large doses of certain drugs on body weight basis.
- B. Their excretory ability of the kidney is less well developed. (Correct Answer)
- C. Their gastric emptying is prolonged.
- D. Their hepatic metabolizing enzyme activity is slower.
Explanation: ***Their excretory ability of the kidney is less well developed.*** - Neonates have **immature renal function** with lower glomerular filtration rate (GFR) and tubular secretion/reabsorption capabilities compared to adults. - This reduced excretory capacity affects the **elimination of renally cleared drugs**, often requiring dose adjustments. - This is a **universally accepted true statement** about neonatal physiology. *Their gastric emptying is prolonged.* - While gastric emptying in neonates is indeed slower and more variable than in adults, the statement as written is **somewhat ambiguous** because "prolonged" could be interpreted different ways. - However, **this statement is also factually TRUE** - neonatal gastric emptying IS prolonged compared to adults. - **Note:** This creates ambiguity as both this and the correct answer are true statements. *They can tolerate large doses of certain drugs on body weight basis.* - This is **FALSE** - Neonates generally have **reduced drug tolerance** compared to adults due to immature organ systems. - They are **more susceptible to adverse drug effects** and typically require lower mg/kg doses for most medications. - This is the only clearly **incorrect** statement among the options. *Their hepatic metabolizing enzyme activity is slower.* - This is **TRUE** - The activity of many hepatic drug-metabolizing enzymes (e.g., **cytochrome P450 enzymes**, glucuronidation) is **reduced at birth**. - This slower metabolism can lead to **prolonged half-lives** and increased drug accumulation. - **Note:** This statement is also factually accurate, creating potential ambiguity. **Clinical Note:** This question has inherent ambiguity as three of the four statements are medically accurate. In exam context, the renal excretion option is selected as it represents the most fundamental and clinically significant difference affecting drug dosing in neonates.
Question 5: All of the following drugs cross the blood-brain barrier, EXCEPT:
- A. Physostigmine
- B. Atropine
- C. Neostigmine (Correct Answer)
- D. Lignocaine
Explanation: ***Neostigmine*** - As a **quaternary ammonium compound**, neostigmine carries a permanent positive charge, making it highly **hydrophilic** and unable to readily cross the **blood-brain barrier (BBB)**. - Its inability to cross the BBB means its effects are primarily limited to the **peripheral nervous system**, particularly at the neuromuscular junction for conditions like myasthenia gravis, or in the gut for paralytic ileus. *Physostigmine* - Physostigmine is a **tertiary amine** that is **lipid-soluble** at physiological pH, allowing it to easily cross the **blood-brain barrier** and exert central nervous system effects. - It is used to treat **central anticholinergic syndrome** because it can reverse the central effects of anticholinergic drugs. *Atropine* - Atropine is a **tertiary amine** that is also **lipid-soluble** and readily crosses the **blood-brain barrier**, leading to significant central nervous system effects such as sedation, excitation, or even delirium at higher doses. - Its ability to cross the BBB contributes to its wide range of systemic anticholinergic effects, including those on the brain. *Lignocaine* - Lignocaine (lidocaine) is a **tertiary amine local anesthetic** that is highly **lipid-soluble** and can readily cross the **blood-brain barrier**. - Its entry into the CNS is responsible for its potential side effects such as **seizures, dizziness, and central nervous system depression** when absorbed systemically.
Question 6: Which of the following is not a component of the Goldman Revised Cardiac Risk Index?
- A. History of preoperative treatment with insulin
- B. History of preoperative serum creatinine >2.0 mg/dL
- C. Age > 80 yrs (Correct Answer)
- D. History of ischemic heart disease
Explanation: ***Age > 80 yrs*** - **Age** is not a parameter included in the Goldman Revised Cardiac Risk Index for predicting postoperative cardiac complications. - The index focuses on specific medical conditions and surgical risk factors. *History of preoperative treatment with insulin* - This is a component of the **Goldman Revised Cardiac Risk Index**, indicating **insulin-dependent diabetes mellitus**. - Diabetes requiring insulin treatment is a significant risk factor for cardiac complications during surgery. *History of preoperative serum creatinine >2.0 mg/dL* - An elevated **serum creatinine** (>2.0 mg/dL) is a recognized component of the index, reflecting **renal insufficiency**. - **Renal impairment** is associated with increased cardiac risk in the perioperative period. *History of ischemic heart disease* - This is a key component of the Goldman Revised Cardiac Risk Index, as a history of **ischemic heart disease** (e.g., prior myocardial infarction, angina) significantly increases perioperative cardiac risk. - Patients with existing heart disease are more susceptible to cardiac events during and after surgery.
Question 7: A mother reports that her daughter ingested a substance in an unknown dose. The girl presents with hypertension, tachycardia, mydriasis, and hyperthermia. What is the most likely substance?
- A. Heroin
- B. Morphine
- C. Cocaine (Correct Answer)
- D. Chlorpheniramine
- E. Organophosphate
Explanation: ***Cocaine*** - The presented symptoms of **hypertension, tachycardia, mydriasis, and hyperthermia** are characteristic of a **sympathomimetic toxidrome**, frequently caused by cocaine overdose. - Cocaine acts as a **norepinephrine-dopamine-serotonin reuptake inhibitor**, leading to excessive stimulation of the central and peripheral nervous systems. *Heroin* - Heroin is an **opioid**, and overdose generally presents with **respiratory depression, bradycardia, miosis (pinpoint pupils)**, and hypotension, which are contrary to the patient's symptoms. - Patients typically exhibit central nervous system **depression**, rather than the hyperactive state seen here. *Morphine* - Similar to heroin, morphine is an **opioid** and causes symptoms like **respiratory depression, bradycardia, miosis**, and hypotension. - These effects are the opposite of the **sympathomimetic** signs observed in the patient. *Chlorpheniramine* - Chlorpheniramine is an **antihistamine** with significant **anticholinergic effects**. An overdose might cause **mydriasis and tachycardia**, but not typically severe hypertension or hyperthermia as the primary features. - Other anticholinergic signs such as **dry mucous membranes, urinary retention, and altered mental status (delirium)** would also be expected. *Organophosphate* - Organophosphate poisoning causes a **cholinergic toxidrome** due to **acetylcholinesterase inhibition**, resulting in excessive cholinergic stimulation. - Classic presentation includes **SLUDGE syndrome** (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) along with **miosis (pinpoint pupils), bradycardia, bronchospasm**, and muscle fasciculations. - These findings are the **opposite** of the sympathomimetic signs seen in this patient.
Question 8: What do A and B represent in the curve shown below?
- A. A= Median effective dose, B= Median lethal dose (Correct Answer)
- B. A= Therapeutic index, B= Median efficacy
- C. A= Median lethal dose, B= Median effective dose
- D. A= Median efficacy, B= Therapeutic index
Explanation: ***A= Median effective dose, B= Median lethal dose*** - **A** corresponds to the **median effective dose (ED50)**, which is the dose that produces a therapeutic effect in 50% of the population - The purple curve represents the dose-response for efficacy; at A, 50% of individuals are responding effectively - **B** corresponds to the **median lethal dose (LD50)**, which is the dose that is lethal to 50% of the population - The red curve represents the dose-response for toxicity/lethality; at B, 50% of individuals are experiencing a lethal outcome *A= Therapeutic index, B= Median efficacy* - The **therapeutic index** is a ratio (LD50/ED50), not a specific dose represented on the x-axis - **Median efficacy** is not a standard pharmacological term to represent a point on a dose-response curve; rather, efficacy refers to the maximal effect a drug can produce *A= Median lethal dose, B= Median effective dose* - This option reverses the correct identification of A and B - **Median effective dose (ED50)** is typically expected at lower doses, while **median lethal dose (LD50)** is at higher doses, indicating toxicity - In the provided graph, the curve for A occurs at a much lower dose range than the curve for B, making it the effective dose, not the lethal dose *A= Median efficacy, B= Therapeutic index* - **Median efficacy** is not a specific dose value represented this way on a dose-response curve - The **therapeutic index** is a ratio, not a dose point on the graph
Question 9: For the treatment of kala-azar, the daily dose of miltefosine in a 3-year-old child who weighs 15 kg is
- A. 20 mg
- B. 40 mg (Correct Answer)
- C. 10 mg
- D. 30 mg
Explanation: ***40 mg*** - Miltefosine dosage for children weighing 12 to 29 kg (including a 15 kg child) is typically **2.5 mg/kg body weight per day orally**. - For a 15 kg child, this translates to 2.5 mg/kg * 15 kg = **37.5 mg**, which is rounded to **40 mg** for practical dosing since miltefosine capsules come in 10 mg or 50 mg sizes. *20 mg* - This dose is lower than the recommended **2.5 mg/kg/day** for a 15 kg child, which would be 37.5 mg. - An underdose of miltefosine could lead to **treatment failure** and the development of drug resistance. *10 mg* - This dose is significantly lower than the recommended therapeutic dose for a 15 kg child, which requires approximately **37.5 mg daily**. - Such a low dose would be **ineffective** in treating kala-azar, risking worsening disease. *30 mg* - While closer than 10 mg or 20 mg, 30 mg is still below the calculated **37.5 mg/day** for a 15 kg child. - An insufficient dose may compromise the efficacy of treatment and lead to **suboptimal parasitic clearance**.
Question 10: Which of the following is a characteristic feature of Werner's syndrome?
- A. Joint laxity
- B. Multiple cancers
- C. Accelerated aging (Correct Answer)
- D. Intestinal polyps
Explanation: ***Premature ageing*** - Werner's disease is characterized by **accelerated aging** and the appearance of age-related diseases at a much younger age [1]. - Patients often present with **sclerosis**, hair graying, and other features associated with advanced age [1]. *Multiple cancer* - While patients with Werner's may have **increased cancer risk**, it is not a direct hallmark of the disease. - The primary feature focuses on **premature aging** rather than a significant predisposition to multiple cancers [1]. *Intestinal polyps* - Intestinal polyps are not typically associated with Werner's disease but are more characteristic of conditions like **Familial adenomatous polyposis (FAP)**. - The main pathology of Werner's lies in the **genetic mechanisms** behind aging, not specifically in gastrointestinal manifestations [1]. *Lax joints* - Although some connective tissue disorders can present with lax joints, this is not a feature of Werner's disease. - Werner's disease primarily involves **age-related changes** rather than joint laxity or hypermobility [1].
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free